April 27, 2020 / 11:56 AM / a month ago

BRIEF-Novocure Announces Presentation Of EF-19 Post-Approval Registry Trial Data

April 27 (Reuters) - Novocure Ltd:

* NOVOCURE ANNOUNCES PRESENTATION OF EF-19 POST-APPROVAL REGISTRY TRIAL DATA STUDYING OPTUNE AS A MONOTHERAPY FOR THE TREATMENT OF RECURRENT GBM AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 2020 VIRTUAL ANNUAL MEETING I

* NOVOCURE LTD - EF-19 DATA CONFIRM EFFECTIVENESS AND SAFETY OF OPTUNE AS MONOTHERAPY AND Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below